推测抗体药物偶联物在阿尔茨海默病中的可能细胞信号转导机制。

Postulating the possible cellular signalling mechanisms of antibody drug conjugates in Alzheimer's disease.

机构信息

School of Health Sciences and Technology, University of Petroleum and Energy Studies, Bidohli, Dehradun, Uttarakhand, India.

出版信息

Cell Signal. 2023 Feb;102:110539. doi: 10.1016/j.cellsig.2022.110539. Epub 2022 Nov 29.

DOI:10.1016/j.cellsig.2022.110539

PMID:36455831

Abstract

Alzheimer's disease (AD) is one of the most common neurodegenerative disorders in the world. Although the basic pathology of the disease is elucidated, it is difficult to restore or prevent the worsening of neurodegeneration and its symptoms. Antibody and small molecule-based approaches have been studied and are in study individually, but a combined approach like conjugation has not been performed to date. The conjugation between antibodies and drugs which are already used for Alzheimer's treatment or developed specifically for this purpose may have better efficacy and dual action in mitigating Alzheimer's disease. A probable mechanism for antibody-drug conjugates in Alzheimer's disease is discussed in the present review.

摘要

阿尔茨海默病（AD）是世界上最常见的神经退行性疾病之一。尽管该病的基本病理已阐明，但要恢复或防止神经退行性变及其症状恶化仍很困难。抗体和小分子为基础的方法已分别进行了研究，但迄今为止尚未采用结合物(conjugation)等联合方法。将已经用于阿尔茨海默病治疗或专门为此目的开发的药物与抗体结合可能具有更好的疗效和双重作用，以减轻阿尔茨海默病。本文综述了抗体药物偶联物在阿尔茨海默病中的可能作用机制。